Abstract | INTRODUCTION: METHODS: We performed an open-label study to explore the tolerability and safety of the combination of glatiramer acetate (GA) and NAC in patients with relapsing-remitting multiple sclerosis at the outpatient MS clinics of the Jewish General Hospital and Hôpital Charles Lemoyne, Montreal, Canada. Seven patients with relapsing-remitting multiple sclerosis with at least one T1 gadolinium-enhancing lesion on screening magnetic resonance imaging were recruited. Treatment consisted of a 10-week run-in period followed by 36-week treatment with a combination of GA 20 mg subcutaneously once daily plus NAC 2.5 g orally twice daily. Outcome measures included safety and tolerability, redox biochemistry, and magnetic resonance imaging effect. RESULTS: Treatment with the combination of GA and NAC was safe and well tolerated. CONCLUSIONS: In light of the favorable safety profile, an efficacy-demonstrating study may be considered.
|
Authors | Hyman M Schipper, Douglas Arnold, Francois GrandʼMaison, Calvin Melmed, Fraser Moore, Mark Levental, Haixiang Su, Michel Constantin, Jean-Louis Stril, Jean Godin |
Journal | Clinical neuropharmacology
(Clin Neuropharmacol)
2015 Jul-Aug
Vol. 38
Issue 4
Pg. 127-31
ISSN: 1537-162X [Electronic] United States |
PMID | 26166235
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Free Radical Scavengers
- Immunosuppressive Agents
- Glatiramer Acetate
- Glutathione
- Acetylcysteine
|
Topics |
- Acetylcysteine
(therapeutic use)
- Adolescent
- Adult
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Free Radical Scavengers
(therapeutic use)
- Glatiramer Acetate
(therapeutic use)
- Glutathione
(blood)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting
(blood, drug therapy)
- Outcome Assessment, Health Care
- Pilot Projects
- Young Adult
|